Jeppe Øvlesen

Born 1962. Øvlesen has experience in business development and has been involved in more than 20 successful start-ups in medtech, biotech, and IT, including CLC Bio, Cetrea and Monsenso. Øvlesen is Co-founder, board member and CEO at SynAct Pharma AB (publ), and has previously been CEO at ChemoMetec A/S and PNN Medical A/S. Previous experience also includes founding TXP Pharma, and holding executive positions as CFO and Vice President of business development at Action Pharma A/S, whose lead candidate was sold to AbbVie for 110 MUSD. Øvlesen is currently chairman in HG Energy Group A/S, Cercare Medical A/S, Go-Pen A/S, and Neurescue ApS, and is a board member in Perfusion Tech Aps, and ResoTher Pharma Aps. Øvlesen has an MBA with a focus on leadership and finance from the University of Hartford, US. Øvlesen is independent of the company, the company management and of major shareholders as defined by the Swedish Code of Corporate Governance.